scorecardresearch
Wednesday, July 23, 2025
TopicRemdesivir

Topic: Remdesivir

Remdesivir trial discovers a Covid weak spot and why this success is critical

In episode 458 of #CutTheClutter, Shekhar Gupta explains the significance of the randomised trial of remdesivir's effectiveness on treating Covid-19.

This is how remdesivir, developed for Hepatitis C and Ebola, fights Covid-19

The experimental antiviral drug that was developed by US pharmaceutical company Gilead Sciences has shown that it leads to faster recovery in Covid-19 patients.

Remdesivir has clear-cut, positive effect on cutting Covid recovery time, says top US doctor

The claims of Dr Anthony Fauci come at the time a study in The Lancet has said ‘remdesivir is not associated with statistically significant clinical benefits’.

Why some experts want more data before they are convinced about remdesivir

Some experts say science has taken a back seat to optimism in the rush to find a way out of the coronavirus crisis that has paralysed economies around the world.

Remdesivir trial shows Covid-19 patients recover faster, could be first effective drug

The US trial looked at whether Gilead’s remdesivir helped people with Covid-19 recover faster than without it.

On Camera

Bihar mimics 19th-century American South. Citizenship is now weaponised to exclude voters

Disenfranchisement by institutional fiat is profoundly undemocratic. The effect of the ECI's new documentary process in Bihar will tilt the scales in favour of the BJP.

India-US set to ink mini trade deal soon, reach understanding on agricultural & dairy products

Mini deal will likely see no cut in 10% baseline tariff on Indian exports announced by Trump on 2 April, it is learnt, but additional 26% tariffs are set to be reduced.

Not just AK-203, India & Russia to jointly manufacture AK-19 and PPK-20 for domestic use and export 

India-Russia JV is also racing to deliver 7,000 more AK-203 assault rifles by 15 Aug. These are currently being made with 50% indigenisation and this will surge to 100% by 31 December.

Strategic partner one day, tactical nightmare the next: India’s learning Trumplomacy the hard way

Public, loud, upfront, filled with impropriety and high praise sometimes laced with insults. This is what we call Trumplomacy. But the larger objective is the same: American supremacy.